Needham Reiterates Hold on Bausch & Lombto Hold
Needham analyst David Saxon reiterates Bausch & Lomb (NYSE:BLCO) from Hold to Hold.
Stocks · News reference
Bausch + Lomb Receives FDA Warning Letter Over Sterile Drug Manufacturing At Tampa Plant, Citing Inadequate Aseptic Controls And Persistent Microbial Contamination; Products Deemed Adulterated
https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/bausch-lomb-inc-732398-09042026
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Leerink Partners Initiates Coverage On Bausch & Lomb with Outperform Rating, Announces Price Target of $24
Leerink Partners analyst Daniel Clark initiates coverage on Bausch & Lomb (NYSE:BLCO) with a Outperform rating and announces Price Target of $24.
Nicox Announces Extension of Cash Runway
Nicox SA announced an extension of its cash runway to beyond Q1 2028 with €8.4 million in cash as of August 31, 2026. The company expects an FDA approval milestone for NCX 470 by April 30, 2027, which would fund operations into 2029, with subsequent royalties potentially extending visibility further. Management changes include Doug Hubatsch transitioning to Chief Scientific Advisor and Siobhan Garbutt assuming leadership of the development team.